Cargando…

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

BACKGROUND: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alten, Rieke, Burkhardt, Harald, Feist, Eugen, Krüger, Klaus, Rech, Juergen, Rubbert-Roth, Andrea, Voll, Reinhard E., Elbez, Yedid, Rauch, Christiane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795278/ https://www.ncbi.nlm.nih.gov/pubmed/29329602 http://dx.doi.org/10.1186/s13075-017-1488-5

Ejemplares similares

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
por: Alten, Rieke, et al.
Publicado: (2023)

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
por: Koehm, Michaela, et al.
Publicado: (2022)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
por: Behrens, Frank, et al.
Publicado: (2021)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
por: Nüßlein, Hubert G., et al.
Publicado: (2015)

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
por: Alten, Rieke, et al.
Publicado: (2022)

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
por: Alten, Rieke, et al.
Publicado: (2014)

Integrative modeling of transcriptional regulation in response to antirheumatic therapy
por: Hecker, Michael, et al.
Publicado: (2009)

An analysis of intra array repeats: the good, the bad and the non informative
por: Elbez, Yedid, et al.
Publicado: (2006)

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
por: Emery, Paul, et al.
Publicado: (2023)

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
por: Nüßlein, Hubert G, et al.
Publicado: (2014)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
por: Sato, Shuzo, et al.
Publicado: (2021)

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
por: Derambure, Céline, et al.
Publicado: (2020)

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis
por: Ghannam, Khetam, et al.
Publicado: (2020)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
por: Ozen, Gulsen, et al.
Publicado: (2019)

Molluscum contagiosum eruption during therapy with methotrexate and abatacept: A clinical and dermoscopic case study
por: Taviti, Franca, et al.
Publicado: (2022)

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
por: Guyot, Patricia, et al.
Publicado: (2011)

Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro
por: Annussek, Tobias, et al.
Publicado: (2012)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
por: Hsieh, Tyng-Shiuan, et al.
Publicado: (2023)

Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases
por: Sehnert, Bettina, et al.
Publicado: (2020)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage
por: Reddig, Annika, et al.
Publicado: (2021)

Daily oral administration of low‐dose methotrexate has greater antirheumatic effects in collagen‐induced arthritis rats
por: Koyama, Aoi, et al.
Publicado: (2017)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
por: Huang, Yinan, et al.
Publicado: (2023)

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
por: Hazlewood, Glen S, et al.
Publicado: (2016)

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jh8v5d07224pq40hg8a92jsrr3